Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
October 30, 2015 7:06 AM EDT
Piper Jaffray upgraded Seattle Genetics (NASDAQ: SGEN) from Underweight to Neutral with a price target of $44.00 (from $30.00).
Analyst Edward Tenthoff commented, "GEN reported ADCETRIS sales of $59 million in 3Q:15 and management again raised 2015 ADCETRIS sales guidance to $218-223 million, and our... More
October 29, 2015 4:17 PM EDT
Seattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $84.1 million versus the consensus estimate of $82.67 million.
ADCETRIS sales in the third quarter of $59.1 million, an increase from $48.2 million in the third... More
October 28, 2015 2:53 PM EDT
(Updated - October 28, 2015 2:54 PM EDT)
The Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Initial Claims - Street sees 264kContinuing Claims - Street sees 2.185MGDP: Adv. - Street sees 1.6%Chain Deflator: Adv. - Street sees 1.3%
Earnings:
A.H. Belo (NYSE: AHC) - no Street consensus
Aetna (NYSE: AET) - consensus EPS $1.77
Air Products (NYSE: APD) -... More
